UNICREDIT BANK/CALL/BIOGEN IDEC/320/0.1/18.06.25 | Real-time BOERSE MUENCHEN 01:42:10 2024-06-07 pm EDT | ||
| 1.24 EUR | -10.14% |
|
| Current month | +15.97% | ||
| 1 month | +40.82% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 1.24 | -10.14% |
| 24-06-06 | 1.38 | -7.38% |
| 24-06-05 | 1.49 | +6.43% |
| 24-06-04 | 1.4 | +5.26% |
| 24-06-03 | 1.33 | +11.76% |
Real-time BOERSE MUENCHEN
Last update June 07, 2024 at 01:42 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD4WFP |
| ISIN | DE000HD4WFP0 |
| Date issued | 2024-04-22 |
| Strike | 320 $ |
| Maturity | 2025-06-18 (376 Days) |
| Parity | 10 : 1 |
| Emission price | 0.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.49 € |
|---|---|
| Lowest since issue | 0.51 € |
| Spread | 0.02 € |
| Spread % | 1.65% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
232
USD
Average target price
284.6
USD
Spread / Average Target
+22.70%
- Stock Market
- Warrants
- Warrant
